The PIPAC-OPC7 Study: The Use of PET/CT Scans as a Method of Evaluation in Patients Treated With PIPAC, a Pilot Study.

Launched by ODENSE UNIVERSITY HOSPITAL · Nov 17, 2023

Keywords

ClinConnect Summary

The PIPAC-OPC7 study is a clinical trial designed to explore the use of special imaging scans called FDG-PET/CT scans in patients with cancer that has spread to the lining of the abdomen, a condition known as peritoneal metastasis. This study will involve 16 patients who are receiving a type of treatment called Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC). The goal is to see if these scans can effectively evaluate how well the treatment is working and to determine if this method is practical for patients.

To be eligible for this trial, participants must be adults over 18 years old with specific types of cancer that have spread to the abdomen and must have a maximum of one other area of cancer outside the abdomen. They should also be in good general health, able to provide consent in Danish, and not currently undergoing other systemic chemotherapy. Participants will receive the PIPAC treatment and have repeated scans to monitor their progress throughout the study. This trial is currently recruiting participants who meet these criteria, and it aims to improve how we assess treatment effectiveness in patients with challenging abdominal cancers.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with synchronous or metachronous histology or cytology proven GC, PC, CRC, or OC with clinical evidence of PM.
• • Patients who are eligible for and offered PIPAC at the discretion of the dedicated multidisciplinary tumor conference and subsequent out-patient evaluation at Odense PIPAC Center
• • Patients with a maximum of one extra-peritoneal metastasis at CT dated within one month of inclusion.
• • Patients in Eastern Cooperative Oncology Group performance status 0-1.
• • Patients \>18 years of age.
• • Patients must be able to give mandatory oral and written consent in Danish.
• Exclusion Criteria:
• • Concomitant systemic chemotherapy (bidirectional treatment).
• • Known allergies to contrast dye.
• • Any other significant disease or disorder which, in the opinion of the investigator, may either put the patient at risk because of participation in the trial, or may influence the results.